Overview
Evidence-based recommendations on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
Last reviewed: 17 August 2022
health technology evaluation 1 has been migrated to antimicrobial resistance guidance 1. The recommendations and accompanying content remain unchanged.
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
This guidance is part of a project with NHS England to test a new health technology evaluation process and payment model for 2 antimicrobial products (cefiderocol and ceftazidime-avibactam).
We tested a bespoke process to develop this guidance (PDF).
Your responsibility
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients.
The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.